Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to take care of Psoriasis Can-Fite BioPharma , a biotechnology business traded on the Tel Aviv STOCK MARKET, an Israeli Biopharmaceutical firm, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful summary of a Stage II dose-response clinical research with CF101 to treat individuals with moderate to severe Psoriasis; the analysis met its primary objective of efficacy and safety successfully pharmacological action . The Phase II study confirmed that CF101 had a clean basic safety profile, a obvious efficacy signal with dose-response data and a fantastic therapeutic index.
Related StoriesGlan Clwyd Medical center N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanningCHOP's Buerger Middle for Advanced Pediatric Care celebrates grand openingACC's public reporting program provides information regarding hospitals' performanceThe authors investigated whether routinely collected data from hospital episode statistics could possibly be used to identify the gynaecologist Rodney Ledward, who was suspended in 1996 and was the subject of the Ritchie inquiry into quality and practice within the NHS. The study team compared the efficiency of 142 gynaecology consultants with the functionality of Ledward over a five yr period, to determine if Ledward was a statistical outlier relating to seven indicators from hospital episode statistics. The indicators were particularly chosen because of their potential link with low quality of service.